Progressive multifocal leukoencephalopathy, usually called PML, is a rare and often devastating brain infection caused by the JC polyomavirus, a virus that quietly inhabits the bodies of most adults without ever causing trouble. PML strikes almost exclusively when the immune system is severely weakened, whether by HIV/AIDS, blood cancers, organ transplantation, or certain immunosuppressive drugs. The disease destroys the fatty insulation around nerve fibers in the brain’s white matter, and without treatment of the underlying immune deficiency, it is frequently fatal. What makes PML particularly unsettling is the gap between how common the virus is and how rare the disease remains, a gap that depends entirely on immune surveillance.
The JC Virus and Why Most People Never Get Sick
Somewhere between half and three-quarters of the adult population carries antibodies to the JC polyomavirus (often abbreviated JCV), meaning they were infected at some point, usually during childhood. The virus persists in the kidneys, lymphoid tissue, and bone marrow for life, shedding harmlessly in urine. In healthy carriers, the immune system keeps JCV in check so effectively that most people never know they are infected.
Research on archival brain tissue has shown that JCV DNA can be found in the brains of people who never developed PML. One study using quantitative PCR detected JCV DNA in roughly a quarter of brain samples from HIV-negative individuals without PML, a rate similar to that found in HIV-positive individuals who also did not have the disease.1PubMed Central. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy This finding suggests the virus can establish latency in the brain well before any immunosuppression occurs, sitting dormant until the immune system falters.
How the Virus Turns Dangerous
The version of JCV circulating harmlessly in urine carries a specific genetic arrangement in its regulatory region, known as the archetype form. When researchers compare virus from the urine of healthy people with virus recovered from the brains and spinal fluid of PML patients, they find a critical difference: the regulatory region in PML-associated virus has been rearranged. These rearrangements are highly diverse from patient to patient, but they share a common consequence. They all boost the virus’s ability to express early genes and replicate faster, particularly in the brain cell types JCV targets.2PubMed Central. Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate
The virus’s primary targets are oligodendrocytes, the cells responsible for producing the myelin sheath that insulates nerve fibers throughout the brain. JCV enters these cells, hijacks their machinery, and eventually destroys them. This lytic destruction of oligodendrocytes is considered the central event driving the demyelination that defines PML.3PubMed Central. Polyomavirus JC infection inhibits differentiation of oligodendrocyte progenitor cells The virus also infects astrocytes and, to a lesser degree, neurons, but it is the loss of oligodendrocytes and their myelin that produces the characteristic white matter damage visible on brain scans and at autopsy.4PubMed. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS)
Who Is at Risk
PML has historically been most closely linked to advanced HIV/AIDS. Before effective antiretroviral therapy became available, HIV was the underlying condition in about 85% of PML cases, and the AIDS pandemic drove roughly a fivefold increase in PML incidence overall.5PubMed. Progressive multifocal leukoencephalopathy The risk of PML in people with HIV is strongly tied to CD4+ T-cell counts; the lower the count, the higher the danger. A French nationwide cohort study documented a drop in PML incidence from about 3.3 cases per 1,000 person-years in the mid-1990s to 1.3 per 1,000 person-years in the 2000s as antiretroviral therapy became standard.6The Journal of Infectious Diseases. Incidence, Clinical Presentation, and Outcome of Progressive Multifocal Leukoencephalopathy in HIV-Infected Patients during the Highly Active Antiretroviral Therapy Era: A Nationwide Cohort Study A Swiss cohort told a similar story, with incidence falling roughly fourfold after 1996.7Clinical Infectious Diseases. Incidence and Outcome of Progressive Multifocal Leukoencephalopathy over 20 Years of the Swiss HIV Cohort Study
That decline in HIV-associated PML, however, has been partly offset by a new category of risk. Certain immunosuppressive drugs, particularly monoclonal antibodies, have been linked to PML in patients with no HIV infection at all. Natalizumab, used to treat multiple sclerosis and Crohn’s disease, drew attention after unexpected PML cases surfaced in clinical use. Rituximab, widely prescribed for non-Hodgkin lymphoma, rheumatoid arthritis, and other conditions, carries a risk estimated at around 4 per 100,000 in rheumatoid arthritis patients.8PubMed. Progressive multifocal leukoencephalopathy in autoimmune diseases Efalizumab, once approved for psoriasis, was eventually withdrawn from the market partly because of PML cases. All three drugs alter immune cell trafficking or deplete specific lymphocyte populations, creating a window for JCV reactivation.9The Lancet Oncology. Progressive multifocal leukoencephalopathy: current updates and future perspectives
What PML Looks and Feels Like
PML usually creeps in rather than announcing itself. Onset is typically insidious, and the symptoms depend entirely on where in the brain the demyelination is occurring. The most common presentations include visual problems, weakness on one side of the body, difficulty with speech, cognitive decline, and trouble coordinating movements.10PubMed. The clinical features of PML Patients with AIDS may additionally show gait disturbance and difficulty swallowing. Because the lesions can appear almost anywhere in the white matter, the clinical picture varies widely from person to person.
Distinguishing PML from a relapse of multiple sclerosis can be genuinely difficult in patients on natalizumab, since both diseases affect white matter. A comparative study found some useful patterns: PML more often presents with hemiparesis and altered thinking, while MS relapses more commonly involve brainstem symptoms, spinal cord involvement, or optic neuritis, none of which were seen in the PML group. On MRI, PML tends to produce large, confluent white matter lesions, whereas MS relapses more often show smaller, discrete lesions. Crescentic lesions in the cerebellum were seen only in PML patients in that study.11JAMA Neurology. Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Diagnosis Through Imaging and Spinal Fluid
MRI is usually the first clue. PML lesions characteristically appear as areas of high signal on T2-weighted images, starting as small punctate spots that can coalesce into larger patches described as a “milky way” pattern. The lesions typically show low signal on T1-weighted images and restricted diffusion at the advancing edge. Emerging evidence suggests that certain susceptibility-weighted imaging findings may serve as an early marker.12PubMed Central. Overview of MRI findings in progressive multifocal leukoencephalopathy Unlike many other brain infections, PML lesions often do not enhance with contrast, although enhancement can be seen when the immune system is reconstituting.
Confirming PML typically requires detecting JCV DNA in the cerebrospinal fluid using PCR. A nested PCR approach can detect as few as 10 copies of JCV DNA in a small volume of spinal fluid, and clinical follow-up studies have confirmed strong agreement between a positive PCR result and clinically evident PML.13PubMed Central. Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy A more recent study found that among patients with positive JCV quantitative PCR results who also had compatible clinical and imaging findings, the positive predictive value was 100%, though nearly half of those patients had viral loads below the lowest reliably quantifiable standard, meaning that even a low-positive result can be meaningful in the right clinical context.14Journal of the Neurological Sciences. Diagnosing progressive multifocal leukoencephalopathy: Positive predictive value of CSF JC virus quantitative PCR and importance of recognizing suggestive neuroimaging findings
When spinal fluid PCR is negative but suspicion remains high, a brain biopsy may be needed. The gold-standard histopathological diagnosis rests on a triad: demyelination, enlarged oligodendrocyte nuclei containing viral inclusions, and bizarre-looking reactive astrocytes, all confirmed by detection of JCV in the tissue.15PubMed Central. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section A large histopathological study of 91 patients reinforced that this classical triad combined with viral detection remains the diagnostic standard, though the morphological appearance of lesions can vary considerably.16PubMed Central. Histomorphological variations in progressive multifocal leukoencephalopathy correlated with JCV replication in brain lesions: insights from 91 patients
Risk Stratification for Natalizumab Users
Because natalizumab is an effective treatment for aggressive multiple sclerosis, neurologists and patients face a difficult balancing act: the drug works well, but it carries a real PML risk. Three factors are used to estimate that risk in practice. The first is whether the patient has antibodies to JCV, since PML essentially does not occur in truly seronegative individuals. The second is how long the patient has been on natalizumab, with risk climbing after roughly two years. The third is whether the patient has previously used other immunosuppressive medications.
To further refine risk among JCV-seropositive patients who have not used prior immunosuppression, clinicians measure the JCV antibody index, a standardized measure of how much anti-JCV antibody the patient has. Research has shown that this index can meaningfully separate higher-risk from lower-risk patients. Among those with an index at or below 0.9, the incidence of PML is substantially lower, and among those with an index at or below 0.6, the incidence in one dataset was actually zero.17PubMed Central. Improving risk-stratification of natalizumab-associated PML Even among patients with prior immunosuppressant exposure, where antibody levels were initially thought less useful, very low index values (at or below 0.45) appear to carry minimal cumulative PML risk.
Another biomarker under investigation is CD62L, a surface protein on T cells. HIV-positive PML patients show significantly lower CD62L expression on their CD4+ T cells compared to HIV-positive patients who did not develop PML, and this reduction does not correlate with CD4 counts or viral load, suggesting it may reflect something specific about PML vulnerability.18PubMed. Specific loss of cellular L-selectin on CD4(+) T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection Validation work in the natalizumab context found that CD62L measurement had 86% sensitivity and 91% specificity for predicting PML, while the JCV antibody index had 100% sensitivity but only 59% specificity.19PubMed. PML risk stratification using anti-JCV antibody index and L-selectin Combining both markers could theoretically improve prediction further, though neither test alone is definitive.
Treatment and the IRIS Problem
PML has no approved antiviral therapy. The cornerstone of management is restoring the patient’s immune function so that their own T cells can fight the virus. For people with HIV, that means starting or optimizing antiretroviral therapy. For patients on immunosuppressive drugs, it means stopping the offending medication as quickly as safely possible. In both scenarios, the goal is the same: rebuild the immune surveillance that was keeping JCV dormant.
This strategy works in many cases, but it comes with a dangerous paradox. As the immune system rebounds, it may mount an overly aggressive inflammatory response against virus-infected brain cells, a condition called immune reconstitution inflammatory syndrome, or IRIS. In PML-IRIS, the newly recovered immune cells, predominantly cytotoxic T cells, flood into the brain and attack oligodendrocytes harboring JCV. The resulting inflammation can cause dramatic clinical worsening, with swelling and tissue damage sometimes worse than what the virus itself was producing.20PubMed. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS) Managing IRIS typically involves corticosteroids to tamp down the inflammation, but the timing and intensity of treatment are judgment calls with no firm consensus.
Numerous drugs have been tried against JCV itself, with disappointing results. Mefloquine, an antimalarial that showed activity against JCV in laboratory settings, failed in a clinical trial. The study was terminated early after interim analysis showed no significant difference between mefloquine and standard care in terms of viral load, clinical improvement, or MRI findings.21Journal of neurovirology. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: Results and exploration of predictors of PML outcomes Mirtazapine, an antidepressant that blocks the serotonin receptor JCV may use to enter brain cells, showed no statistically significant benefit in cohort analyses either, though some researchers noted a possible signal in natalizumab-associated PML specifically.22PubMed. Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine
Checkpoint Inhibitors and Adoptive T-Cell Therapy
The most promising recent development in PML treatment has come from an unexpected direction: cancer immunotherapy. Pembrolizumab, a checkpoint inhibitor that blocks PD-1, was tested in PML patients based on the idea that exhausted T cells in PML might be reinvigorated, much as they are in cancer. In a small initial study of eight patients, five showed clinical improvement or stabilization, accompanied by drops in JCV viral load in the spinal fluid and increases in JCV-specific T-cell activity.23PubMed. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy That five-of-eight response rate was encouraging enough to generate real excitement in a disease with no approved therapy.
Subsequent work has sharpened the picture. A study examining virus-specific T-cell status alongside checkpoint inhibitor treatment found that patients who had detectable JCV-specific T cells showed dramatically higher response rates, around 86%, compared to about 23% in patients who lacked detectable virus-specific T cells.24JAMA Neurology. Virus-Specific T Cells and Response to Checkpoint Inhibitors in Progressive Multifocal Leukoencephalopathy Survival differences were equally stark. This suggests that checkpoint inhibitors work best when there are JCV-specific T cells to unleash, not when the immune repertoire has been wiped clean.
That insight has led researchers to explore combining pembrolizumab with adoptive transfer of virus-specific T cells, essentially providing the immune ammunition the checkpoint inhibitor needs. A case report described clinical improvement in a PML patient treated with both pembrolizumab and donor-derived BK virus-specific T cells (BK virus is closely related to JCV, so its T cells cross-react). The authors proposed that this combination should be studied in larger trials.25PubMed Central. Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Case Report This is still very early-stage evidence, but it represents the clearest therapeutic direction PML research has had in decades.
Prognosis and Life After PML
Survival estimates depend heavily on the underlying condition and whether immune function can be restored. Across both HIV-positive and HIV-negative patients, one-year survival has been estimated at roughly 50% to 60%.26PubMed Central. Determinants of survival in progressive multifocal leukoencephalopathy Among HIV-positive patients, those whose CD4+ counts were above 200 at the time of PML diagnosis had better one-year survival (about 67%) compared to those with counts below 200 (about 48%). Patients who mounted a detectable JCV-specific cytotoxic T-cell response within three months of diagnosis also fared better, with estimated one-year survival of 73%.
For those who do survive, the picture is mixed. A study following 24 long-term PML survivors found that about a third ended up with no significant disability despite lingering symptoms, while another quarter remained independent with mild disability. On the other end, about a fifth required constant assistance or were institutionalized. Full neurological recovery was uncommon, occurring in fewer than one in five patients, and those with cerebellar involvement tended to do worse.27PubMed Central. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy Surviving PML, in other words, often means living with permanent cognitive or motor deficits.
JC Virus Granule Cell Neuronopathy
PML is not the only brain disease JCV can cause. A distinct syndrome called JC virus granule cell neuronopathy (JCV GCN) was identified in patients presenting with progressive cerebellar atrophy but without the classic white-matter damage of PML. In these cases, MRI showed shrinkage of the cerebellum without white matter lesions, and biopsy revealed that the virus was selectively infecting the granule cell layer of the cerebellum rather than oligodendrocytes.28PubMed. JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy
The viral strains found in JCV GCN patients carry specific mutations in the VP1 capsid protein, the outermost part of the virus that determines which cells it can enter. These mutations appear to redirect the virus’s tropism away from oligodendrocytes and toward neurons. Several distinct VP1 mutations have been characterized across reported cases, all clustering in the same region of the protein.29Journal of General Virology. JC virus granule cell neuronopathy is associated with VP1 C terminus mutants The clinical implication is that JCV is not a one-trick pathogen. It can mutate in ways that shift its target cells, producing distinct diseases depending on which part of the brain it infects. For clinicians, JCV GCN is worth remembering in any immunocompromised patient with unexplained cerebellar degeneration and a normal-appearing white matter on MRI.
The Drug Holiday Question for Natalizumab
Because PML risk with natalizumab rises with duration of treatment, a natural question arises: could patients take periodic breaks from the drug to reset their risk? The idea of a “drug holiday” was explored observationally, and the results were discouraging. A study of patients with very active relapsing-remitting MS who paused natalizumab found that disease activity rebounded, sometimes severely, during the interruption. The data did not support the concept of a drug holiday as a practical safety strategy.30PubMed. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients Patients and neurologists are left with a harder decision: stay on a drug that controls the disease effectively while monitoring PML risk carefully, or switch to a different therapy that may be less effective but carries no PML risk. That trade-off remains one of the more difficult conversations in MS care, and it is one reason the risk-stratification tools discussed earlier carry real practical weight.